Biotechnology - Merck & Co

Filter

Current filters:

Merck & Co

Popular Filters

1 to 25 of 41 results

Merck enters into collaboration with NGM to develop biologics

Merck enters into collaboration with NGM to develop biologics

24-02-2015

Pharma giant Merck & Co has entered into a collaboration with privately-held biotech company NGM Biopharmaceuticals…

BiotechnologyMerck & CoNGM BiopharmaceuticalsResearchUSA

NewLink earns $20 million Ebola vaccine milestone from Merck

19-02-2015

US biotech firm NewLink Genetics says it had received notification from pharma giant Merck & Co that…

BiotechnologyFinancialMerck & CoNewLink GeneticsResearchTropical diseasesVaccines

Hospira’s biosimilar Inflectra comparable to Remicade in IBD treatment

Hospira’s biosimilar Inflectra comparable to Remicade in IBD treatment

19-02-2015

Positive data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first…

BiosimilarsBiotechnologyGastro-intestinalsHospiraInflectraJohnson & JohnsonMerck & CoRemicadeResearch

Merck & Co inks discovery and development deal with Moderna

Merck & Co inks discovery and development deal with Moderna

13-01-2015

Privately-held Moderna Therapeutics has entered into a license and collaboration agreement with US pharma…

Anti-viralsBiotechnologyFinancialMerck & CoModerna TherapeuticsResearchUSAVaccines

NewLink Genetic and Merck Ebola collaboration gets $30 million government award

23-12-2014

US biotech firm NewLink Genetics saw its shares gain 4.1% to $40.11 in morning trading on Monday, following…

Anti-viralsBiotechnologyFinancialMerck & CoNewLink GeneticsResearchTropical diseasesUSA

Merck & Co in up to $375 million deal to acquire OncoEthix

Merck & Co in up to $375 million deal to acquire OncoEthix

19-12-2014

US pharma giant Merck & Co said yesterday that it has acquired, through a subsidiary, Swiss-based privately…

BiotechnologyMerck & CoMergers & AcquisitionsOncoEthixOncologyOTX015

Official: Merck & Co to acquire Cubist for $8.4 billion

Official: Merck & Co to acquire Cubist for $8.4 billion

08-12-2014

Confirming weekend speculation and rumors, US pharma giant Merck & Co this morning said it has entered…

Antibiotics and Infectious diseasesBiotechnologyCubicinCubist PharmaceuticalsMerck & CoMergers & AcquisitionsZerbaxa

Merck gains rights to NewLink Genetics investigational Ebola vaccine

24-11-2014

US pharma giant Merck & Co has entered into an exclusive worldwide license agreement to research, develop,…

Anti-viralsBiotechnologyGlobalLicensingMerck & CoNewLink GeneticsResearchrVSV-EBOYTropical diseases

ESMO 2014: Merck's Keytruda and B-MS' Opdivo

ESMO 2014: Merck's Keytruda and B-MS' Opdivo

30-09-2014

Early results from pharma giant Merck & Co on the use of its Keytruda (pembrolizumab) in patients with…

BiotechnologyBristol-Myers SquibbKeytrudaMerck & CoMerck Research LaboratoriesOncologyOpdivoResearchSpain

Advaxis and Merck & Co collaborate on prostate cancer

Advaxis and Merck & Co collaborate on prostate cancer

26-08-2014

US cancer immunotherapies firm Advaxis has entered into a clinical trial collaboration agreement with…

AdvaxisADXS-PSABiotechnologyLicensingMerck & CoOncologypembrolizumabResearch

Merck & Co in new accord with Bionomics for CNS research

Merck & Co in new accord with Bionomics for CNS research

24-06-2014

Australian biotech firm Bionomics has entered into a second exclusive research collaboration and license…

BionomicsBiotechnologyBNC375LicensingMerck & CoNeurologicalResearch

Immunotherapies show promise for non-small cell lung cancer market

Immunotherapies show promise for non-small cell lung cancer market

13-06-2014

Immunotherapies have huge potential for the treatment of non-small cell lung cancer (NSCLC), with three…

BiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & ConivolumabOncologypembrolizumabResearchRoche

Merck & Co enters deal with Agenus worth a potential $100 million in milestones

Merck & Co enters deal with Agenus worth a potential $100 million in milestones

28-04-2014

USA-based biotech firm Agenus has entered into a collaboration and license agreement with pharma giant…

AgenusBiotechnologyLicensingMerck & CoOncologyResearch

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co

05-02-2014

World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

Alnylam to acquire Merck’s Sirna Therapeutics

Alnylam to acquire Merck’s Sirna Therapeutics

13-01-2014

US RNAi therapeutics specialist Alnylam Pharmaceuticals says it has reached agreement to acquire US pharma…

Alnylam PharmaceuticalsBiotechnologyMerck & CoMergers & AcquisitionsSirna Therapeutics

First biosimilar monoclonal antibody approved in Europe

10-09-2013

US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

Bionomics in $172 million pain treatment deal with US pharma giant

01-08-2013

Australian biotech firm Bionomics (ASX: BNO) has entered an agreement with US pharma giant Merck & Co…

BionomicsBiotechnologyLicensingMerck & CoNeurologicalPharmaceuticalResearch

New Zealand consults on Victrelis listing and some Pegasys amendments

19-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

UK's NICE recommends hepatitis C treatment for children

18-07-2013

In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

US FDA accepts Merck & Co's BLA ragweed pollen allergy immunotherapy

09-05-2013

US pharma giant Merck & Co (NYSE: MRK) revealed yesterday (May 8) that the Biologics License Application…

Alk-AbelloBiotechnologyImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

1 to 25 of 41 results

COMPANY SPOTLIGHT

Menarini

Back to top